India plays down Trump’s tariff threat
New Delhi on Friday sought to play down US President Donald Trump's recent statement targeting India and other nations on import duties and announcing reciprocal tariffs from April 2.
New Delhi on Friday sought to play down US President Donald Trump's recent statement targeting India and other nations on import duties and announcing reciprocal tariffs from April 2.
In what is expected to upset New Delhi after Prime Minister Narendra Modi's recent successful visit to Washington, US President Donald Trump targeted India and other countries on import duties and announced reciprocal tariffs from April 2.
Ahead of his visit to US, the Congress on Tuesday took a jibe at Prime Minister Narendra Modi over the “inhuman treatment” meted out to Indian illegal immigrants who were sent from America recently, saying this has never happened before.
Stock market fell on Monday amid losses in global markets as the US President Donald Trump announced new tariffs on key trading partners, including Canada, Mexico, and China.
Madonna criticizes the Trump administration for rolling back freedoms. Her comments come after recent executive orders targeting LGBTQ+ protections and diversity initiatives.
In a scathing review of the Trump campaign's arguments that the president was cheated in his November 3 reelection bid, three appeals court judges unanimously said that allegations of unfairness were not supported by evidence.
Trump has made an unprecedented attempt to defy the results of the election by refusing to concede, spreading wild theories about stolen ballots and launching baseless legal challenges that have been thrown out by courts.
Biden transition executive director Yohannes Abraham said in the statement that the president-elect's team would now move quickly, with Murphy's decision also formally allowing for coordination with current government officials.
He picked Avril Haines, the former deputy CIA director, as his director of national intelligence, the first woman to ever hold that position.
The green light for drugmaker Regeneron came after REGEN-COV2, a combination of two lab-made antibodies, was shown to reduce Covid-19-related hospitalizations or emergency room visits in patients with underlying conditions.
